ClinicalTrials.gg
CompletedNCT03370133BE VIVIDUpdated Apr 15, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Bimekizumab and Ustekinumab in Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis and Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 105 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
3rd of 14
567 · median 210
Started
2017
with 1 other
Phase 3
8 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 4th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis
  • Psoriatic Arthritis

Keywords

  • Bimekizumab
  • PSO
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be at least 18 years of age
  • Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit
  • Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5-point scale
  • Subject is a candidate for systemic PSO therapy and/or phototherapy
  • Female subject of child bearing potential must be willing to use highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections
  • Subject has concurrent acute or chronic viral or C or (HIV) infection
  • Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
  • Presence of active suicidal ideation or positive suicide behavior
  • Presence of moderately severe major depression or severe major depression
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    Bimekizumab cohort

    Subjects will receive bimekizumab for 52 weeks.

    Drug: Bimekizumab

  • Active comparator
    Ustekinumab cohort

    Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.

    Drug: Ustekinumab · Other: Placebo

  • Placebo comparator
    Placebo

    Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Bimekizumab will be provided at pre-specified time intervals.

    Also known as: UCB4940

  • Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.

    Also known as: Stelara®

  • OtherPlacebo

    Subjects will receive Placebo at pre-specified time points.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 16.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With a PASI100 Response at Week 16

    The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  2. Percentage of Participants With an IGA 0 Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] with at least a two-category improvement from Baseline at Week 16.

    Time frame: Week 16

  3. Percentage of Participants With a PASI75 Response at Week 4

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 4

  4. Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16

    As Patient-Reported-Outcome (PRO) measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.

    Time frame: Week 16

  5. Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16

    A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.

    Time frame: Week 16

  6. Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16

    As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.

    Time frame: Week 16

  7. Percentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline

    Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

    Time frame: Week 16

  8. Percentage of Participants With a PASI90 Response at Week 12

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 12

  9. Percentage of Participants With a PASI90 Response at Week 52

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 52

  10. Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 12

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 12.

    Time frame: Week 12

  11. Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 52.

    Time frame: Week 52

  12. Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

    The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)

  13. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

    The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)

  14. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

    The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)

  15. Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

    The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Week 16 to Safety Follow-Up (up to 52 weeks duration)

  16. Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

    The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Week 16 to Safety Follow-Up (up to 52 weeks duration)

  17. Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

    The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

    Time frame: From Week 16 to Safety Follow-Up (up to 52 weeks duration)

07

Results

Posted Feb 3, 2022

Participant flow

This study started to enroll participants in December 2017 and concluded in December 2019.

Initial Treatment Period (WK 16)
Participant flow — Initial Treatment Period (WK 16)
MilestonePlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Placebo/Bimekizumab 320 mg Q4WBimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4WUstekinumab/Ustekinumab
Started83321163000
Completed74306157000
Not completed9156000
Withdrew: Adverse event552000
Withdrew: Death111000
Withdrew: Lack of efficacy210000
Withdrew: Protocol violation002000
Withdrew: Lost to follow-up030000
Withdrew: Withdrawal by subject121000
Withdrew: Non-compliance010000
Withdrew: Site closed020000
Maintenance Treatment Period (WK 52)
Participant flow — Maintenance Treatment Period (WK 52)
MilestonePlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Placebo/Bimekizumab 320 mg Q4WBimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4WUstekinumab/Ustekinumab
Started00074306157
Completed00069283141
Not completed00052316
Withdrew: Adverse event0003124
Withdrew: Lack of efficacy000014
Withdrew: Protocol violation000110
Withdrew: Lost to follow-up000043
Withdrew: Withdrawal by subject000144
Withdrew: Non-compliance000010
Withdrew: Consent withdrawn for imp not procedures000001

Outcome measures

PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 164.885.049.7
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 99.869 · 95% CI 34.020 to 293.175
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 6.056 · 95% CI 3.874 to 9.466
PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 164.884.153.4
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 118.762 · 95% CI 36.701 to 384.307
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 4.809 · 95% CI 3.096 to 7.470
SecondaryPercentage of Participants With a PASI100 Response at Week 16

The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI100 Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a PASI100 Response at Week 16058.620.9
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 25.590 · 95% CI 9.063 to 72.253
SecondaryPercentage of Participants With an IGA 0 Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] with at least a two-category improvement from Baseline at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA 0 Response at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With an IGA 0 Response at Week 16058.622.1
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 25.471 · 95% CI 9.020 to 71.925
SecondaryPercentage of Participants With a PASI75 Response at Week 4

The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response at Week 4
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a PASI75 Response at Week 42.476.915.3
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 123.020 · 95% CI 29.394 to 514.862
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 18.202 · 95% CI 10.998 to 30.123
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Pain at Week 16

As Patient-Reported-Outcome (PRO) measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 1616.777.368.2
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 16.258 · 95% CI 7.356 to 35.931
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Itch at Week 16

A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 1613.176.665.8
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 22.279 · 95% CI 9.795 to 50.674
SecondaryPercentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16

As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 1612.778.559.5
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 23.049 · 95% CI 10.201 to 52.077
SecondaryPercentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline

Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline15.384.270.5
Statistical analysis
  • Placebo (RS) vs Bimekizumab 320 mg Q4W (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs PBO) were based on the CMH test from the general association.) · Odds ratio (or): 37.696 · 95% CI 16.920 to 83.987
SecondaryPercentage of Participants With a PASI90 Response at Week 12

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI90 Response at Week 12
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a PASI90 Response at Week 122.485.043.6
Statistical analysis
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 8.047 · 95% CI 5.107 to 12.679
SecondaryPercentage of Participants With a PASI90 Response at Week 52

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI90 Response at Week 52
percentage of participantsBimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With a PASI90 Response at Week 5281.955.8
Statistical analysis
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 3.795 · 95% CI 2.442 to 5.899
SecondaryPercentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 12

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 12
percentage of participantsPlacebo (RS)Bimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 124.881.952.1
Statistical analysis
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 4.379 · 95% CI 2.850 to 6.730
SecondaryPercentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline at Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52
percentage of participantsBimekizumab 320 mg Q4W (RS)Ustekinumab (RS)
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 5278.260.7
Statistical analysis
  • Bimekizumab 320 mg Q4W (RS) vs Ustekinumab (RS) · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups (BKZ 320 mg Q4W vs Ustekinumab) were based on the CMH test from the general association.) · Odds ratio (or): 2.412 · 95% CI 1.573 to 3.699
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)Ustekinumab (SS)
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period238.41 (169.53 to 325.91)287.26 (246.93 to 332.29)247.62 (197.23 to 306.96)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)Ustekinumab (SS)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period7.97 (0.97 to 28.80)5.06 (1.64 to 11.80)10.14 (3.29 to 23.66)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period

The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
no. of new events per 100 subject-yearsPlacebo (SS)Bimekizumab 320 mg Q4W (SS)Ustekinumab (SS)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period24.39 (8.95 to 53.09)6.08 (2.23 to 13.24)5.99 (1.24 to 17.52)
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
no. of new events per 100 subject-yearsPlacebo/Bimekizumab 320 mg Q4W (MS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W (MS)Ustekinumab/Ustekinumab (MS)
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period149.35 (114.24 to 191.85)127.84 (111.58 to 145.81)111.24 (90.80 to 134.91)
SecondaryNumber of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
no. of new events per 100 subject-yearsPlacebo/Bimekizumab 320 mg Q4W (MS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W (MS)Ustekinumab/Ustekinumab (MS)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period9.88 (3.21 to 23.05)6.19 (3.30 to 10.58)7.46 (3.22 to 14.70)
SecondaryNumber of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period

The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.

Time frame:
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Reported as:
Number · no. of new events per 100 subject-years
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
no. of new events per 100 subject-yearsPlacebo/Bimekizumab 320 mg Q4W (MS)Bimekizumab 320 mg Q4W/Bimekizumab 320 mg Q4W (MS)Ustekinumab/Ustekinumab (MS)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period5.91 (1.22 to 17.27)5.72 (2.95 to 9.99)3.71 (1.01 to 9.51)

Adverse events

Collected over Treatment-emergent AEs were collected from Baseline to Safety Follow Up (up to Week 68). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Initial Period (SS)1/83 (1.2%)2/83 (2.4%)17/83 (20.5%)
Bimekizumab 320 mg Q4W Initial Period (SS)1/321 (0.3%)5/321 (1.6%)87/321 (27.1%)
Ustekinumab Initial Period (SS)1/163 (0.6%)5/163 (3.1%)37/163 (22.7%)
Any Bimekizumab 320 mg Q4W (AMS)2/395 (0.5%)24/395 (6.1%)192/395 (48.6%)
Any Ustekinumab (AMS)1/163 (0.6%)13/163 (8%)73/163 (44.8%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPlacebo Initial Period (SS)Bimekizumab 320 mg Q4W Initial Period (SS)Ustekinumab Initial Period (SS)Any Bimekizumab 320 mg Q4W (AMS)Any Ustekinumab (AMS)
Tendon injuryInjury, poisoning and procedural complications1/830/3210/1630/3950/163
Toxicity to various agentsInjury, poisoning and procedural complications1/830/3210/1630/3950/163
Oesophageal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/830/3210/1630/3950/163
Cardiac arrestCardiac disorders0/831/3211/1631/3951/163
Macular holeEye disorders0/830/3211/1630/3951/163
HaemorrhoidsGastrointestinal disorders0/830/3210/1630/3951/163
Wound infectionInfections and infestations0/830/3211/1630/3951/163
Urinary tract infectionInfections and infestations0/830/3211/1630/3951/163
MastoiditisInfections and infestations0/830/3210/1630/3951/163
Otitis externaInfections and infestations0/830/3210/1630/3951/163
Most frequent other events
Most frequent other events
EventPlacebo Initial Period (SS)Bimekizumab 320 mg Q4W Initial Period (SS)Ustekinumab Initial Period (SS)Any Bimekizumab 320 mg Q4W (AMS)Any Ustekinumab (AMS)
NasopharyngitisInfections and infestations7/8330/32114/16386/39536/163
Oral candidiasisInfections and infestations0/8328/3210/16360/3951/163
Upper respiratory tract infectionInfections and infestations2/839/3215/16336/39518/163
HeadacheNervous system disorders0/8311/3217/16316/39510/163
HypertensionVascular disorders1/837/3215/16314/39510/163
Urinary tract infectionInfections and infestations5/836/3211/16312/3956/163
PsoriasisSkin and subcutaneous tissue disorders5/833/3212/1639/3952/163
Back painMusculoskeletal and connective tissue disorders2/833/3214/16310/3959/163

Baseline characteristics

Baseline characteristics refer to the Randomized Set (RS) consisting of all participants randomized into the study.

Age, Categorical
Age, Categorical(Participants)PlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Total Title
<=18 years0213
Between 18 and 65 years73285144502
>=65 years10341862
Age, Continuous
Age, Continuous(years)PlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Total Title
Mean49.7 ± 13.645.2 ± 14.046.0 ± 13.646.1 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Total Title
Female239246161
Male60229117406
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBimekizumab (BKZ) 320 Milligrams (mg) Q4WUstekinumab (Uste)Total Title
American Indian/Alaskan native0112
Asian207136127
Black09312
White63237120420
Other/mixed0336
08

Study locations

105 sites
  • Ps0009 946
    Phoenix, Arizona 85032, United States
  • Ps0009 910
    Bakersfield, California 93309, United States
  • Ps0009 919
    San Diego, California 92103, United States
  • Ps0009 906
    Boca Raton, Florida 33486, United States
  • Ps0009 909
    Boynton Beach, Florida 33437, United States
  • Ps0009 912
    Coral Gables, Florida 33134, United States
  • Ps0009 907
    Miami, Florida 33144, United States
  • Ps0009 903
    Ocala, Florida 34471, United States
  • Ps0009 921
    Ormond Beach, Florida 32174, United States
  • Ps0009 918
    Tampa, Florida 33612, United States
  • Ps0009 941
    Alpharetta, Georgia 30022, United States
  • Ps0009 911
    Plainfield, Indiana 46168, United States
  • Ps0009 900
    West Des Moines, Iowa 50265, United States
  • Ps0009 905
    Overland Park, Kansas 66215, United States
  • Ps0009 922
    Baton Rouge, Louisiana 70809, United States
  • Ps0009 917
    Troy, Michigan 48084, United States
  • Ps0009 915
    St Louis, Missouri 63117, United States
  • Ps0009 958
    Omaha, Nebraska 68144, United States
  • Ps0009 901
    Portsmouth, New Hampshire 03801, United States
  • Ps0009 908
    East Windsor, New Jersey 08520, United States
  • Ps0009 923
    Albuquerque, New Mexico 87106, United States
  • Ps0009 913
    New York, New York 10029-65, United States
  • Ps0009 920
    Portland, Oregon 97210, United States
  • Ps0009 924
    Houston, Texas 77004, United States
  • Ps0009 914
    San Antonio, Texas 78213, United States
  • Ps0009 004
    Fremantle, Australia
  • Ps0009 005
    Phillip, Australia
  • Ps0009 002
    Westmead, Australia
  • Ps0009 009
    Woolloongabba, Australia
  • Ps0009 050
    Brussels, Belgium
  • Ps0009 052
    Liège, Belgium
  • Ps0009 051
    Loverval, Belgium
  • Ps0009 673
    Halifax, Canada
  • Ps0009 652
    Oakville, Canada
  • Ps0009 651
    Richmond Hill, Canada
  • Ps0009 650
    Surrey, Canada
  • Ps0009 653
    Toronto, Canada
  • Ps0009 657
    Waterloo, Canada
  • Ps0009 218
    Bonn, Germany
  • Ps0009 209
    Darmstadt, Germany
  • Ps0009 214
    Erlangen, Germany
  • Ps0009 208
    Frankfurt am Main, Germany
  • Ps0009 210
    Friedrichshafen, Germany
  • Ps0009 211
    Hamburg, Germany
  • Ps0009 212
    Heidelberg, Germany
  • Ps0009 213
    Mahlow, Germany
  • Ps0009 205
    Osnabrück, Germany
  • Ps0009 217
    Schweinfurt, Germany
  • Ps0009 254
    Budapest, Hungary
  • Ps0009 255
    Budapest, Hungary
  • Ps0009 253
    Orosháza, Hungary
  • Ps0009 259
    Szekszárd, Hungary
  • Ps0009 300
    Roma, Italy
  • Ps0009 303
    Roma, Italy
  • Ps0009 629
    Asahikawa, Japan
  • Ps0009 605
    Bunkyō City, Japan
  • Ps0009 607
    Chiyoda City, Japan
  • Ps0009 610
    Chūōku, Japan
  • Ps0009 601
    Fukuoka, Japan
  • Ps0009 619
    Gifu, Japan
  • Ps0009 620
    Hamamatsu, Japan
  • Ps0009 608
    Itabashi-Ku, Japan
  • Ps0009 627
    Itabashi-Ku, Japan
  • Ps0009 609
    Kobe, Japan
  • Ps0009 600
    Kurume, Japan
  • Ps0009 622
    Matsumoto, Japan
  • Ps0009 604
    Minatoku, Japan
  • Ps0009 623
    Morioka, Japan
  • Ps0009 621
    Nagoya, Japan
  • Ps0009 625
    Nankoku, Japan
  • Ps0009 624
    Obihiro, Japan
  • Ps0009 611
    Osaka, Japan
  • Ps0009 614
    Osaka, Japan
  • Ps0009 603
    Sapporo, Japan
  • Ps0009 617
    Sendai, Japan
  • Ps0009 613
    Shimotsuke, Japan
  • Ps0009 602
    Shinagawa-Ku, Japan
  • Ps0009 612
    Shinjuku-Ku, Japan
  • Ps0009 618
    Shinjuku-Ku, Japan
  • Ps0009 626
    Shinjuku-Ku, Japan
  • Ps0009 628
    Shinjuku-Ku, Japan
  • Ps0009 615
    Sumida City, Japan
  • Ps0009 606
    Takaoka, Japan
  • Ps0009 616
    Tsu, Japan
  • Ps0009 362
    Bialystok, Poland
  • Ps0009 369
    Bialystok, Poland
  • Ps0009 371
    Bydgoszcz, Poland
  • Ps0009 358
    Katowice, Poland
  • Ps0009 357
    Kielce, Poland
  • Ps0009 372
    Lodz, Poland
  • Ps0009 374
    Poznan, Poland
  • Ps0009 350
    Warsaw, Poland
  • Ps0009 351
    Warsaw, Poland
  • Ps0009 367
    Wroclaw, Poland
  • Ps0009 370
    Wroclaw, Poland
  • Ps0009 400
    Moscow, Russia
  • Ps0009 402
    Moscow, Russia
  • Ps0009 403
    Moscow, Russia
  • Ps0009 404
    Saint Petersburg, Russia
  • Ps0009 556
    Cardiff, United Kingdom

Showing the first 100 of 105 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Asahina A, Okubo Y, Morita A, Tada Y, Igarashi A, Langley RG, Deherder D, Matano M, Vanvoorden V, Wang M, Ohtsuki M, Nakagawa H. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatol Ther (Heidelb). 2023 Mar;13(3):751-768. doi: 10.1007/s13555-022-00883-y. Epub 2023 Jan 17. PubMed 36648594 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaci D. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429. PubMed 37950894 ↗
  • Strober B, Boehncke WH, Krueger JG, Magnolo N, Vender R, Warren RB, Lopez Pinto JM, Kavanagh S, Hoepken B, Gisondi P. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials. Dermatol Ther (Heidelb). 2025 Dec;15(12):3633-3650. doi: 10.1007/s13555-025-01557-1. Epub 2025 Oct 8. PubMed 41060492 ↗
  • Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, Lopez Pinto JM, Wixted K, Thaci D. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatol Ther (Heidelb). 2026 Jan;16(1):585-603. doi: 10.1007/s13555-025-01595-9. Epub 2025 Dec 8. PubMed 41359217 ↗
  • Krueger JG, Cutcutache I, Lebwohl M, Gudjonsson JE, Pinter A, Langley RG, Merola J, Tada Y, Skelton A, Rastrick J, Ferecsko AS, Page M, Davies O, Lopez Pinto JM, Warham R, Shaw S, Warren RB. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. J Allergy Clin Immunol. 2026 Apr;157(4):905-916. doi: 10.1016/j.jaci.2025.12.1013. Epub 2026 Jan 22. PubMed 41580158 ↗
  • Gisondi P, Elewski B, Pinter A, Yamaguchi Y, Gooderham M, Kavanagh S, Wixted K, Cross N, Szilagyi B, Merola JF. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. J Dermatolog Treat. 2026 Dec;37(1):2637344. doi: 10.1080/09546634.2026.2637344. Epub 2026 Mar 9. PubMed 41800601 ↗
  • Merola JF, Warren RB, Thaci D, Gordon KB, Nishida E, Strober B, Conrad C, Kavanagh S, Lopez Pinto JM, Hoepken B, Gisondi P. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov;26(6):967-979. doi: 10.1007/s40257-025-00968-2. Epub 2025 Aug 31. PubMed 40886218 ↗
  • Blauvelt A, Langley RG, Lebwohl M, Strober B, Warren RB, Puig L, Morita A, Gordon KB, Fernandez-Penas P, Kavanagh S, Lopez Pinto JM, Lambert J, Hoepken B, Deherder D, Cross N, Thaci D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep;93(3):644-653. doi: 10.1016/j.jaad.2025.04.038. Epub 2025 Apr 24. PubMed 40286813 ↗
  • Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. PubMed 39578348 ↗
  • Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Korber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089. PubMed 36751950 ↗
  • Warren RB, Gottlieb AB, Merola JF, Garcia L, Cioffi C, Peterson L, Pelligra C, Ciaravino V. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatol Ther (Heidelb). 2021 Oct;11(5):1551-1569. doi: 10.1007/s13555-021-00570-4. Epub 2021 Jul 14. PubMed 34260044 ↗
  • Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. PubMed 33549193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jan 2019, 13 months.

Results were first posted in Feb 2022, 3 years after primary completion. A results delay was requested in Jan 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 13 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 12, 2017
StartActual
Dec 6, 2017
Primary completionActual
Jan 8, 2019
CompletionActual
Dec 13, 2019
Results delay requested
Jan 7, 2020
Results first posted
Feb 3, 2022
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03370133
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Dec 6, 2017
Primary completion
Jan 8, 2019
Completion
Dec 13, 2019
Results posted
Feb 3, 2022
Last update
Apr 15, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion